Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

Fig. 5

AGI-134 protects mice from secondary tumor development and improves survival in a JB/RH melanoma model. Anti-Gal-expressing α1,3GT−/− mice were grafted with 5 × 105 JB/RH cells to create a 1° tumor on one flank and 2 × 104 JB/RH cells on the contralateral flank. 4–5 days after grafting, the 1° tumors were treated once with 1 mg AGI-134 or PBS and contralateral tumor development (a) and mouse survival (b) monitored. Pooled data from three independent experiments are shown. Statistical differences between treatment groups were analyzed by Mantel-Cox test (*p < 0.05). The solid arrows indicate the day of AGI-134 or mock treatment (Day 4 or 5)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us